UNSPSC 51313220: Pirdonium bromide

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30NO.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5123Q291S5, chemically known as 1,1-dimethyl-2-(((p-methyl-alpha-phenylbenzyl)oxy)methyl)piperidinium bromide but more generally known as pirdonium bromide, which bears US NIH Compound Identifier 3047852. European Medicines Agency schedules Pirdonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09901MIG.

UNSPSC 51313220 Pirdonium bromide is a Commodity code, but the recent state and local opportunities tagged under it do not involve pirdonium bromide at all. Instead, the code captures pharmaceutical procurement activity focused on naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products procured by counties, state health agencies, and multistate cooperative purchasing alliances. The work being solicited spans pharmaceutical supply agreements, community health support initiatives, and pharmacy benefit program modernization rather than any single chemical compound. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The code does not show concentration among a single buyer; instead, it reflects diverse public-sector pharmacy and health procurement across multiple jurisdictions and administrative levels.

Geographic activity concentrates in Florida, Texas, and Minnesota with multistate reach through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date and may reflect a data-entry error in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multistate contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities, with weighted evaluation favoring price competitiveness at 75 percent and contract effectiveness set for July 1, 2026.